MDXG
MIMEDX GROUP, INC.
NASDAQ · Healthcare · Biotechnology · US
$3.97
+0.51%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 303.7M | 418.6M | 348.9M | 321.5M | 267.8M |
| Cost of Revenue | 69.0M | 73.0M | 60.1M | 54.6M | 48.3M |
| Gross Profit | 234.7M | 345.6M | 288.8M | 266.8M | 219.5M |
| Operating Expenses | |||||
| R&D Expense | 14.5M | 15.1M | 12.3M | 12.7M | 12.7M |
| SG&A Expense | 244.4M | 266.2M | 216.4M | 216.3M | 220.8M |
| General & Admin Expense | 22.7M | — | — | — | — |
| Selling & Marketing Expense | 90.3M | — | — | — | — |
| Other Expenses | 592.0K | — | 1.2M | 762.0K | 701.0K |
| Total Operating Expenses | 259.5M | 281.3M | 229.9M | 229.7M | 234.3M |
| Cost and Expenses | 328.6M | 354.7M | 290.0M | 284.4M | 282.6M |
| Operating Income (EBIT) | (25.1M) | 63.9M | 58.9M | 37.1M | (14.7M) |
| Non-Operating | |||||
| Interest Income | 3.6M | 4.7M | — | — | — |
| Interest Expense | 1.0M | 1.8M | 1.0M | 6.5M | 5.0M |
| Net Interest Income | 2.6M | 2.9M | (1.0M) | (6.5M) | (5.0M) |
| Other Non-Op Income/Expense | 2.8M | 2.4M | (1.6M) | (6.5M) | (5.0M) |
| Non-Operating Income (excl Interest) | (1.8M) | (4.2M) | (446.0K) | 26.0K | 4.0K |
| EBT (Pre-Tax Income) | (22.4M) | 66.3M | 57.3M | 30.6M | (19.7M) |
| Income Tax Expense | (3.2M) | 17.7M | 15.3M | (36.8M) | 206.0K |
| Bottom Line | |||||
| Net Income | (19.2M) | 48.6M | 42.4M | 67.4M | (30.2M) |
| Earnings from Cont. Ops | (19.2M) | 48.6M | 42.0M | 67.4M | (20.0M) |
| Earnings from Discont. Ops | — | — | 421.0K | — | (10.2M) |
| Bottom Line Net Income | (19.2M) | 48.6M | 42.4M | 55.8M | (36.8M) |
| Per Share | |||||
| Basic EPS | ($0.13) | $0.33 | $0.29 | $0.48 | ($0.27) |
| Diluted EPS | ($0.13) | $0.32 | $0.28 | $0.38 | ($0.27) |
| Revenue Per Share | $2.08 | $2.83 | $2.37 | $2.76 | $2.37 |
| Shares | |||||
| Basic Shares Outstanding | 145.9M | 147.8M | 147.0M | 116.5M | 112.9M |
| Diluted Shares Outstanding | 145.9M | 149.7M | 149.0M | 146.0M | 112.9M |
| Profitability Metrics | |||||
| EBITDA | (16.9M) | 82.9M | 65.4M | 40.5M | (10.7M) |
| D&A | 7.8M | 14.9M | 6.0M | 3.4M | 4.0M |
| EBIT | (23.3M) | 68.0M | 59.3M | 37.1M | (14.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026